

alberico Catapano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6029089/publications.pdf>

Version: 2024-02-01

640
papers

65,835
citations

2802

94
h-index

947

239
g-index

683
all docs

683
docs citations

683
times ranked

50794
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEM2015 studies. Archives of Medical Science, 2023, 19, 1214-1227.	0.9	2
2	Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review. Cardiovascular Drugs and Therapy, 2023, 37, 585-598.	2.6	6
3	Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From ADA VINCI. Cardiovascular Drugs and Therapy, 2023, 37, 941-953.	2.6	6
4	Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. European Journal of Preventive Cardiology, 2022, 28, 2030-2037.	1.8	8
5	Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 578-586.	3.0	14
6	One year after the ESC/EAS guidelines on cholesterol control. What's the new evidence? What's missing?. European Journal of Internal Medicine, 2022, 95, 1-4.	2.2	4
7	Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. European Journal of Preventive Cardiology, 2022, 29, 721-729.	1.8	5
8	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. Rheumatology International, 2022, 42, 261-271.	3.0	5
9	Prevention guidelines and EAS/ESC guidelines for the treatment of dyslipidaemias: A look to the future. Atherosclerosis, 2022, 340, 51-52.	0.8	5
10	The year in cardiovascular medicine 2021: dyslipidaemia. European Heart Journal, 2022, , .	2.2	9
11	New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, 29, 161-166.	2.3	11
12	Targeted proteomics improves cardiovascular risk prediction in secondary prevention. European Heart Journal, 2022, 43, 1569-1577.	2.2	55
13	PCSK9 promotes arterial medial calcification. Atherosclerosis, 2022, 346, 86-97.	0.8	14
14	Nutraceuticals for Dyslipidaemia and Glucometabolic Diseases: What the Guidelines Tell Us (and Do) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	4.1	9
15	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	13.7	69
16	Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes, Obesity and Metabolism, 2022, 24, 868-880.	4.4	38
17	The zebrafish model system for dyslipidemia and atherosclerosis research: Focus on environmental/exposome factors and genetic mechanisms. Metabolism: Clinical and Experimental, 2022, 129, 155138.	3.4	9
18	Understanding the efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2022, 29, 829-831.	1.8	2

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. Journal of Clinical Lipidology, 2022, 16, 286-297.	1.5	20
20	How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?. Atherosclerosis, 2022, 349, 136-143.	0.8	9
21	Potentially Inappropriate Prescribing among Elderly Outpatients: Evaluation of Temporal Trends 2012-2018 in Piedmont, Italy. International Journal of Environmental Research and Public Health, 2022, 19, 3612.	2.6	2
22	Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations. Journal of the American Heart Association, 2022, 11, e023668.	3.7	12
23	Impact of metabolic disorders on the structural, functional, and immunological integrity of the blood-brain barrier: Therapeutic avenues. FASEB Journal, 2022, 36, e22107.	0.5	16
24	Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. European Journal of Preventive Cardiology, 2022, 29, 804-814.	1.8	46
25	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events. Annals of Medicine, 2022, 54, 1036-1046.	3.8	9
26	Interleukin 1 receptor 8 deficiency does not impact atherosclerosis. Thrombosis and Haemostasis, 2022, 0, .	3.4	0
27	Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group. Atherosclerosis, 2022, 349, 233-239.	0.8	9
28	Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label) Tj ETQq0 0 0 rgBT /Overlook 10 Tf 5	0.8	9
29	Adherence to the Mediterranean Diet: Impact of Geographical Location of the Observations. Nutrients, 2022, 14, 2040.	4.1	19
30	Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia. Expert Opinion on Biological Therapy, 2022, 22, 813-820.	3.1	6
31	Targeted Plasma Proteomics to Predict the Development of Carotid Plaques. Stroke, 2022, 53, .	2.0	5
32	New and Emerging Therapies for Dyslipidemia. Endocrinology and Metabolism Clinics of North America, 2022, , .	3.2	3
33	Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. Journal of Internal Medicine, 2021, 290, 116-128.	6.0	21
34	Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression. Cardiovascular Research, 2021, 117, 2069-2082.	3.8	31
35	Insights from ORION studies: focus on inclisiran safety. Cardiovascular Research, 2021, 117, 24-26.	3.8	6
36	Metabolic adaptations of cells at the vascular-immune interface during atherosclerosis. Molecular Aspects of Medicine, 2021, 77, 100918.	6.4	13

#	ARTICLE	IF	CITATIONS
37	Worldwide Changes in Total Cholesterol and Non-HDL-Cholesterol Trends Indicate Where the Challenges Are for the Coming Years. <i>Clinical Chemistry</i> , 2021, 67, 30-32.	3.2	5
38	Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis. <i>Cardiovascular Research</i> , 2021, 117, 1033-1045.	3.8	33
39	Update on Lipids and Lipoproteins—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 400.	7.4	1
40	Gut Microbiota Functional Dysbiosis Relates to Individual Diet in Subclinical Carotid Atherosclerosis. <i>Nutrients</i> , 2021, 13, 304.	4.1	16
41	Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (Bifidobacterium longum BB536, Red) Tj ETQq1 4.0.784314 rgBT /Ove	4.0	14
42	Effect of Lipids and Lipoproteins on Hematopoietic Cell Metabolism and Commitment in Atherosclerosis. <i>Immunometabolism</i> , 2021, 3, e210014.	1.6	16
43	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. <i>Atherosclerosis</i> , 2021, 320, 1-9.	0.8	11
44	Inflammaging and neurodegenerative diseases: Role of NLRP3 inflammasome activation in brain atherosclerotic vascular disease. <i>Mechanisms of Ageing and Development</i> , 2021, 195, 111467.	4.6	14
45	Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe. <i>Atherosclerosis</i> , 2021, 322, 77-81.	0.8	8
46	Role of Bempedoic Acid in Clinical Practice. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 853-864.	2.6	71
47	HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases. <i>Cells</i> , 2021, 10, 1061.	4.1	23
48	Global epidemiology of dyslipidaemias. <i>Nature Reviews Cardiology</i> , 2021, 18, 689-700.	13.7	290
49	Reduction of Cardio-Metabolic Risk and Body Weight through a Multiphasic Very-Low Calorie Ketogenic Diet Program in Women with Overweight/Obesity: A Study in a Real-World Setting. <i>Nutrients</i> , 2021, 13, 1804.	4.1	22
50	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021, 325, 99-109.	0.8	83
51	The year 2020 in Atherosclerosis. <i>Atherosclerosis</i> , 2021, 326, 35-44.	0.8	1
52	HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role. <i>Cells</i> , 2021, 10, 1869.	4.1	46
53	A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice. <i>Frontiers in Immunology</i> , 2021, 12, 701275.	4.8	7
54	Omega-3 for Cardiovascular Diseases: Where Do We Stand After REDUCE-IT and STRENGTH?. <i>Circulation</i> , 2021, 144, 183-185.	1.6	10

#	ARTICLE	IF	CITATIONS
55	Clinical decision support system for lipid metabolism disorders: relevance and potential. Russian Journal of Cardiology, 2021, 26, 4539.	1.4	0
56	PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction. European Heart Journal, 2021, 42, 3078-3090.	2.2	50
57	Hyperglycemic condition mimics tgrls lipid accumulation in cardiomyocytes derived from human-IPSCS. Atherosclerosis, 2021, 331, e124.	0.8	0
58	Cardiovascular immune-inflammatory markers and cellular aging in the general population. Atherosclerosis, 2021, 331, e35.	0.8	0
59	Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression. Atherosclerosis, 2021, 331, e33.	0.8	0
60	Lipoprotein remnants: to be or not to be. European Heart Journal, 2021, 42, 4844-4846.	2.2	4
61	PCSK9 deficiency and heart metabolism. Atherosclerosis, 2021, 331, e15.	0.8	1
62	Observational multicenter study on effectiveness and tolerability of alirocumab in real world, The Omero study: Interim data from the fist 352 participants. Atherosclerosis, 2021, 331, e166.	0.8	0
63	Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe “ Methodology and rationale for the multinational observational SANTORINI study. Atherosclerosis Plus, 2021, 43, 24-30.	0.7	17
64	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies“a consensus statement from the European Atherosclerosis Society. European Heart Journal, 2021, 42, 4791-4806.	2.2	303
65	Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study. Journal of Clinical Medicine, 2021, 10, 4472.	2.4	2
66	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet, The, 2021, 398, 1713-1725.	13.7	142
67	Global, regional, and national burden of stroke and its risk factors, 1990“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurology, The, 2021, 20, 795-820.	10.2	2,308
68	EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. European Journal of Preventive Cardiology, 2021, 28, 1279-1289.	1.8	369
69	Proteomics-Enabled Deep Learning Machine Algorithms Can Enhance Prediction of Mortality. Journal of the American College of Cardiology, 2021, 78, 1621-1631.	2.8	25
70	Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors. Current Atherosclerosis Reports, 2021, 23, 79.	4.8	23
71	Molecular Immune-Inflammatory Connections between Dietary Fats and Atherosclerotic Cardiovascular Disease: Which Translation into Clinics?. Nutrients, 2021, 13, 3768.	4.1	5
72	Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: Implications for clinical diagnosis. Journal of Clinical Lipidology, 2021, 15, 822-831.	1.5	7

#	ARTICLE	IF	CITATIONS
73	Integrative Analysis of Multi-Omics and Genetic Approaches – A New Level in Atherosclerotic Cardiovascular Risk Prediction. <i>Biomolecules</i> , 2021, 11, 1597.	4.0	10
74	Recent insights into low-density lipoprotein metabolism and therapy. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2021, 24, 120-126.	2.5	7
75	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. <i>Atherosclerosis</i> , 2021, 338, 55-63.	0.8	8
76	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2021, 50, 401-411.	1.4	18
77	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAm 2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5656.	2.4	9
78	The Association of Proprotein Convertase Subtilisin/Kexin Type 9 to Plasma Low-Density Lipoproteins: An Evaluation of Different Methods. <i>Metabolites</i> , 2021, 11, 861.	2.9	0
79	341 Observational multicentre study on effectiveness and tolerability of Alirocumab in real world, the OMERO study: interim data from the first 699 patients. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
80	Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 234-243.	1.8	10
81	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 50-67.	11.4	114
82	Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism. <i>European Heart Journal</i> , 2020, 41, 2487-2497.	2.2	50
83	Statins increase Lp(a) plasma level: is this clinically relevant?. <i>European Heart Journal</i> , 2020, 41, 2285-2287.	2.2	14
84	Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 593-603.	1.8	224
85	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	2.2	4,871
86	Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: Need for customisation strategies. <i>Pharmacological Research</i> , 2020, 155, 104514.	7.1	20
87	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 217.	6.1	169
88	Dietary linoleic acid and human health: Focus on cardiovascular and cardiometabolic effects. <i>Atherosclerosis</i> , 2020, 292, 90-98.	0.8	213
89	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 496-517.	2.3	119
90	Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 181-205.	1.8	148

#	ARTICLE	IF	CITATIONS
91	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. Journal of Clinical Lipidology, 2020, 14, 649-659.e6.	1.5	70
92	Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction. Current Atherosclerosis Reports, 2020, 22, 74.	4.8	9
93	Lipids and Lipoproteins in 2020. JAMA - Journal of the American Medical Association, 2020, 324, 595.	7.4	73
94	Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiology, 2020, 5, 1124.	6.1	128
95	Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. Atherosclerosis, 2020, 312, 72-78.	0.8	25
96	Impact of PCSK9 on human-IPSC derived cardiomyocyte mitochondrial function and metabolism. Atherosclerosis, 2020, 315, e86.	0.8	0
97	Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trials. Atherosclerosis, 2020, 315, e12-e13.	0.8	7
98	The cardiovascular benefit of Lp(a) reduction: not there yet. European Heart Journal, 2020, 41, 4256-4258.	2.2	3
99	The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering. Circulation, 2020, 142, 827-837.	1.6	44
100	P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors. Cancer Research, 2020, 80, 3906-3919.	0.9	36
101	Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease. Journal of Clinical Medicine, 2020, 9, 2289.	2.4	19
102	Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy. Expert Opinion on Biological Therapy, 2020, 20, 1477-1489.	3.1	2
103	Can EPA evaporate plaques?. European Heart Journal, 2020, 41, 3933-3935.	2.2	6
104	Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations. Journal of the American Heart Association, 2020, 9, e018189.	3.7	4
105	Bempedoic Acid Efficacy and Safety in High CVD Risk Patients Treated With or Without Ezetimibe: Pooled Analysis of 4 Phase 3 Clinical Trials. Journal of Clinical Lipidology, 2020, 14, 569-570.	1.5	0
106	Factors that Influence Bempedoic Acid-Mediated Reductions in High-sensitivity C reactive Protein: Analysis of Pooled Patient-level Data from Phase 3 Clinical Trials. Journal of Clinical Lipidology, 2020, 14, 577.	1.5	0
107	Bempedoic Acid and Glycemic Control: A Pooled Analysis of 4 Phase 3 Clinical Trials. Journal of Clinical Lipidology, 2020, 14, 577-579.	1.5	2
108	Safety, Tolerability, and Pharmacokinetics of Evinacumab, an Angiopoietin-Like Protein 3 Inhibitor, in Healthy Japanese and Caucasian Subjects. Journal of Clinical Lipidology, 2020, 14, 581.	1.5	0

#	ARTICLE	IF	CITATIONS
109	Efficacy and Safety of Bempedoic Acid in Elderly Patients: Pooled Analyses from Phase 3 Trials. <i>Journal of Clinical Lipidology</i> , 2020, 14, 583.	1.5	0
110	Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. <i>European Heart Journal</i> , 2020, 41, 3998-4007.	2.2	68
111	Global Burden of Cardiovascular Diseases and Risk Factors, 1990â€“2019. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2982-3021.	2.8	4,468
112	A pragmatic controlled trial to improve the appropriate prescription of drugs in adult outpatients: design and rationale of the EDU.RE.DRUG study. <i>Primary Health Care Research and Development</i> , 2020, 21, .	1.2	4
113	A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. <i>Atherosclerosis</i> , 2020, 314, 33-40.	0.8	27
114	New Pharmacological Approaches to Target PCSK9. <i>Current Atherosclerosis Reports</i> , 2020, 22, 24.	4.8	41
115	The year 2019 in Atherosclerosis. <i>Atherosclerosis</i> , 2020, 299, 67-75.	0.8	1
116	Multifactorial Activation of NLRP3 Inflammasome: Relevance for a Precision Approach to Atherosclerotic Cardiovascular Risk and Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4459.	4.1	22
117	The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. <i>Gerontology</i> , 2020, 66, 447-459.	2.8	4
118	Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2020, 160, 105060.	7.1	30
119	Beyond LDL-C levels, does remnant cholesterol estimation matter?. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1088-1090.	1.8	8
120	LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters. <i>Atherosclerosis</i> , 2020, 297, 8-15.	0.8	12
121	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. <i>Atherosclerosis</i> , 2020, 294, 46-61.	0.8	137
122	LDL-Cholesterol-Lowering Therapy. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	1.8	8
123	Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: A population-based study. <i>Atherosclerosis</i> , 2020, 301, 1-7.	0.8	11
124	Prevalence Of familial hypercholeSTERolaemia (FH) in Italian Patients with coronary artERY disease: The POSTER study. <i>Atherosclerosis</i> , 2020, 308, 32-38.	0.8	8
125	Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk. <i>Atherosclerosis Supplements</i> , 2020, 42, e1-e5.	1.2	5
126	Lipid Clinics Network. Rationale and design of the EAS global project. <i>Atherosclerosis Supplements</i> , 2020, 42, e6-e8.	1.2	9

#	ARTICLE	IF	CITATIONS
127	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGram2015 study. <i>Atherosclerosis Supplements</i> , 2020, 42, e15-e24.	1.2	18
128	Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. <i>Atherosclerosis Supplements</i> , 2020, 42, e30-e34.	1.2	6
129	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. <i>Atherosclerosis Supplements</i> , 2020, 42, e49-e58.	1.2	23
130	Balancing cardiovascular benefit and diabetogenic harm of therapy with statins: Real-world evidence from Italy. <i>Diabetes Research and Clinical Practice</i> , 2020, 164, 108197.	2.8	3
131	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	2.2	776
132	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>Russian Journal of Cardiology</i> , 2020, 25, 3826.	1.4	199
133	185-OR: Efficacy and Safety of Bempedoic Acid in Patients with Diabetes, Prediabetes, and Normoglycemia: Analysis of Pooled Patient-Level Data from Four Phase 3 Clinical Trials. <i>Diabetes</i> , 2020, 69, .	0.6	1
134	Design and rationale of a nationwide screening analysis from the LIPIDOGram2015 and LIPIDOGEn2015 studies. <i>Archives of Medical Science</i> , 2020, 18, 604-616.	0.9	9
135	How registers could enhance knowledge and characterization of genetic dyslipidaemias: The experience of the LIPiGen in Italy and of other networks for familial hypercholesterolemia. <i>Atherosclerosis Supplements</i> , 2020, 42, e35-e40.	1.2	10
136	Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool. <i>Atherosclerosis Supplements</i> , 2020, 42, e65-e71.	1.2	8
137	Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. <i>Atherosclerosis Supplements</i> , 2020, 42, e59-e64.	1.2	8
138	“Diet and lifestyle”™ in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members. <i>Atherosclerosis Supplements</i> , 2020, 42, e9-e14.	1.2	2
139	Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies. <i>Atherosclerosis Supplements</i> , 2020, 42, e41-e48.	1.2	8
140	Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy. <i>Atherosclerosis Supplements</i> , 2020, 42, e25-e29.	1.2	1
141	Abstract 14248: Efficacy and Safety of Bempedoic Acid in Patients Who Cannot Tolerate Statins: Pooled Analysis of 4 Phase 3 Clinical Trials. <i>Circulation</i> , 2020, 142, .	1.6	0
142	Abstract 13130: Efficacy and Safety of Bempedoic Acid by Sex: Pooled Analyses From Phase 3 Trials. <i>Circulation</i> , 2020, 142, .	1.6	0
143	PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. <i>European Heart Journal</i> , 2019, 40, 357-368.	2.2	124
144	Treatment with fibrates is associated with higher LAL activity in dyslipidemic patients. <i>Pharmacological Research</i> , 2019, 147, 104362.	7.1	4

#	ARTICLE	IF	CITATIONS
145	Apolipoprotein B Particles and Cardiovascular Disease. JAMA Cardiology, 2019, 4, 1287.	6.1	299
146	Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. Cardiovascular Research, 2019, 115, 510-518.	3.8	63
147	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. Atherosclerosis Supplements, 2019, 39, e1-e8.	1.2	31
148	Understanding the Patient Perception of Statin Experience: A Qualitative Study. Advances in Therapy, 2019, 36, 2723-2743.	2.9	4
149	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, 140-205.	0.8	1,753
150	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2019, 322, 1381.	7.4	144
151	Life-Style And Cardio-Metabolic Profile Of A Population Living In A Clustered Alpine Village (The Plic) Tj ETQq1 1 0.784314 rgBT /Overl	0.8	1
152	Association of Triglyceride-Lowering <i>LPL</i> Variants and LDL-Câ€“Lowering <i>LDLR</i> Variants With Risk of Coronary Heart Disease. JAMA - Journal of the American Medical Association, 2019, 321, 364.	7.4	460
153	Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation. Stroke, 2019, 50, 1758-1765.	2.0	23
154	Atherogenic markers in predicting cardiovascular risk and targeting residual cardiovascular risk. Atherosclerosis: X, 2019, 1, 100001.	0.0	3
155	Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease. Atherosclerosis: X, 2019, 39, 100002.	0.0	9
156	Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. Atherosclerosis, 2019, 286, 40-45.	0.8	7
157	Lifestyle interventions and nutraceuticals: Guideline-based approach to cardiovascular disease prevention. Atherosclerosis: X, 2019, 1, 100003.	0.0	5
158	Cholesterol metabolism, pancreatic Î²-cell function and diabetes. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2149-2156.	3.8	76
159	The Interconnection Between Immuno-Metabolism, Diabetes, and CKD. Current Diabetes Reports, 2019, 19, 21.	4.2	28
160	Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes. Frontiers in Immunology, 2019, 10, 571.	4.8	43
161	Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. New England Journal of Medicine, 2019, 380, 1022-1032.	27.0	529
162	Mendelian Randomization Study of <i>ACLY</i> and Cardiovascular Disease. New England Journal of Medicine, 2019, 380, 1033-1042.	27.0	216

#	ARTICLE	IF	CITATIONS
163	Pentraxin 3 deficiency protects from the metabolic inflammation associated to diet-induced obesity. Cardiovascular Research, 2019, 115, 1861-1872.	3.8	36
164	Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. Pharmacological Research, 2019, 143, 143-150.	7.1	25
165	Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation: the role of HDL. Current Opinion in Lipidology, 2019, 30, 462-469.	2.7	18
166	Why is hypercholesterolaemia so prevalent? A view from evolutionary medicine. European Heart Journal, 2019, 40, 2825-2830.	2.2	8
167	Increasing high-density lipoprotein cholesterol levels for cardiovascular benefit: The end of a dream?. European Journal of Preventive Cardiology, 2019, 26, 531-532.	1.8	5
168	Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 2019, 280, 109-117.	0.8	40
169	Lipid Lowering and Incidence of Cataract, a Role for Fibrates. Clinical Pharmacology and Therapeutics, 2019, 105, 318-319.	4.7	1
170	High-density lipoprotein cholesterol levels, cardiovascular disease risk, and cancer: a relation which does not apply to all?. Cardiovascular Research, 2019, 115, 6-7.	3.8	3
171	Biological Consequences of Dysfunctional HDL. Current Medicinal Chemistry, 2019, 26, 1644-1664.	2.4	65
172	Zc3h10 is a novel mitochondrial regulator. EMBO Reports, 2018, 19, .	4.5	23
173	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis, 2018, 271, 120-127.	0.8	31
174	The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. Current Atherosclerosis Reports, 2018, 20, 12.	4.8	67
175	Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. Pharmacological Research, 2018, 130, 1-11.	7.1	22
176	Atherogenic lipoproteins as treatment targets. Nature Reviews Cardiology, 2018, 15, 75-76.	13.7	3
177	The challenge of risk prediction: How good are we?. European Journal of Preventive Cardiology, 2018, 25, 418-419.	1.8	4
178	Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey. International Journal of Cardiology, 2018, 252, 193-198.	1.7	34
179	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 119-127.	3.0	17
180	Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	2.2	262

#	ARTICLE	IF	CITATIONS
181	Proprotein Convertase Subtilisin Kexin 9 Inhibitors. <i>Cardiology Clinics</i> , 2018, 36, 241-256.	2.2	5
182	New prospects for PCSK9 inhibition?. <i>European Heart Journal</i> , 2018, 39, 2600-2601.	2.2	13
183	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2018, 39, 1131-1143.	2.2	171
184	Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. <i>European Heart Journal</i> , 2018, 39, 3521-3527.	2.2	44
185	Disease trends over time and CD4 + CCR5 + T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 53-63.	2.6	31
186	Good adherence to therapy with statins reduces the risk of adverse clinical outcomes even among very elderly. Evidence from an Italian real-life investigation. <i>European Journal of Internal Medicine</i> , 2018, 47, 25-31.	2.2	12
187	Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. <i>European Heart Journal</i> , 2018, 39, 2540-2545.	2.2	113
188	The long pentraxin 3 (PTX3) plays a key role in the immunomodulation of diet induced-obesity in mice. <i>Atherosclerosis</i> , 2018, 275, e16.	0.8	0
189	The PCSK9/LDLR axis impacts insulin secretion and glucose response. <i>Atherosclerosis</i> , 2018, 275, e55.	0.8	0
190	Reprint of: Impact of Lipids on Cardiovascular Health. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2980-2995.	2.8	17
191	Familial Hypercholesterolemia. , 2018, , 285-297.		0
192	Familial hypercholesterolemia treatments: Guidelines and new therapies. <i>Atherosclerosis</i> , 2018, 277, 483-492.	0.8	128
193	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.8	163
194	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. <i>Atherosclerosis</i> , 2018, 277, 413-418.	0.8	48
195	Coronary disease prevention: towards a more personalised approach. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1884-1886.	1.8	0
196	Multilevel models to estimate standard intima-media thickness curves for individual cardiovascular risk evaluation. <i>Atherosclerosis</i> , 2018, 275, e67.	0.8	0
197	A mendelian randomization study comparing the effect of low-density lipoproteins and triglyceride-rich very low-density lipoproteins on the risk of coronary heart disease. <i>Atherosclerosis</i> , 2018, 275, e78-e79.	0.8	2
198	Clinical and genetic features of familial hypercholesterolemia in pediatric patients: The lipigen Study. <i>Atherosclerosis</i> , 2018, 275, e98-e99.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>European Heart Journal</i> , 2018, 39, 3641-3653.	2.2	69
200	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. <i>Clinical Chemistry</i> , 2018, 64, 1006-1033.	3.2	189
201	Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk “ Results from the PROG-IMT collaboration. <i>PLoS ONE</i> , 2018, 13, e0191172.	2.5	51
202	PCSK9 deficiency results in altered glucose control and increased ectopic fat accumulation in experimental models and in humans. <i>Atherosclerosis</i> , 2018, 275, e2.	0.8	1
203	Impact of Lipids on Cardiovascular Health. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1141-1156.	2.8	272
204	Use of proton pump inhibitors and risk of ischemic events in the general population. <i>Atherosclerosis</i> , 2018, 277, 123-129.	0.8	21
205	Epidemiology of cardiovascular risk factors in two population-based studies. <i>Atherosclerosis Supplements</i> , 2018, 35, e14-e20.	1.2	6
206	Myeloid apolipoprotein E controls dendritic cell antigen presentation and T cell activation. <i>Nature Communications</i> , 2018, 9, 3083.	12.8	95
207	PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?. <i>European Heart Journal</i> , 2018, 39, 2586-2588.	2.2	10
208	High density lipoprotein cholesterol and cancer: Marker or causative?. <i>Progress in Lipid Research</i> , 2018, 71, 54-69.	11.6	79
209	PCSK9 Deficiency Reduces Insulin Secretion and Promotes Glucose Intolerance: the Role of the LDL Receptor. <i>Atherosclerosis Supplements</i> , 2018, 32, 21.	1.2	0
210	OBSOLETE: Familial Hypercholesterolemia. , 2018, , .		0
211	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. <i>European Heart Journal</i> , 2017, 38, ehv480.	2.2	137
212	Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 379-395.	2.6	52
213	Obesity-Induced Metabolic Stress Leads to Biased Effector Memory CD4 + T Cell Differentiation via PI3K p110 β -Akt-Mediated Signals. <i>Cell Metabolism</i> , 2017, 25, 593-609.	16.2	124
214	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	2.2	2,292
215	Management of Dyslipidemias in Europe and the USA: Same Evidence, Different Conclusions? Can We Find Common Ground?. <i>Current Cardiology Reports</i> , 2017, 19, 49.	2.9	2
216	Practical aspects in the management of statin-associated muscle symptoms (SAMS). <i>Atherosclerosis Supplements</i> , 2017, 26, 45-55.	1.2	21

#	ARTICLE	IF	CITATIONS
217	Pitavastatin and HDL: Effects on plasma levels and function(s). <i>Atherosclerosis Supplements</i> , 2017, 27, e1-e9.	1.2	21
218	Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 187-195.	2.6	19
219	Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. <i>British Journal of Pharmacology</i> , 2017, 174, 3973-3985.	5.4	105
220	Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2017, 106, 55-67.	1.9	45
221	Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials. <i>Scientific Reports</i> , 2017, 7, 45788.	3.3	12
222	Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 396-406.	2.6	111
223	Antidrug Antibodies in Patients Treated with Alirocumab. <i>New England Journal of Medicine</i> , 2017, 376, 1589-1590.	27.0	73
224	Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?. <i>Molecular Therapy</i> , 2017, 25, 2435-2437.	8.2	1
225	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). <i>Atherosclerosis Supplements</i> , 2017, 29, 11-16.	1.2	53
226	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. <i>Atherosclerosis Supplements</i> , 2017, 29, 17-24.	1.2	65
227	Impaired fatty acid synthesis affects immune cells activation: focus on sterol regulatory element binding factor-1c on T lymphocytes. <i>Atherosclerosis</i> , 2017, 263, e23.	0.8	0
228	Influence of PCSK9 on biological behavior of mouse smooth muscle cells. <i>Atherosclerosis</i> , 2017, 263, e63.	0.8	0
229	Apolipoprotein E orchestrates T Naïve to T Effector memory cell polarization by modulating the crosstalk between systemic and immune cells lipid metabolism. <i>Atherosclerosis</i> , 2017, 263, e84.	0.8	0
230	The predimed score: index of adherence to the mediterranean diet in the general population: The PLIC study. <i>Atherosclerosis</i> , 2017, 263, e92.	0.8	1
231	Role of PCSK9 (proprotein convertase subtilisin/kexin type 9) beyond LDLR targeting: Focus on glucose metabolism. <i>Atherosclerosis</i> , 2017, 263, e102.	0.8	0
232	Characterization of metabolic syndrome in PLIC cohort. <i>Atherosclerosis</i> , 2017, 263, e181.	0.8	0
233	Detection of familial hypercholesterolemia in patients from a general practice database. <i>Atherosclerosis Supplements</i> , 2017, 29, 25-30.	1.2	21
234	Effector memory T cells predict atherosclerosis progression and cardiovascular events over 4 years follow-up. <i>Atherosclerosis</i> , 2017, 263, e59.	0.8	0

#	ARTICLE	IF	CITATIONS
235	miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways. <i>Cardiovascular Research</i> , 2017, 113, 1627-1638.	3.8	62
236	Clinician interview results about the experiences of their patients who report side effects with statin treatment. <i>Atherosclerosis</i> , 2017, 263, e247.	0.8	0
237	Strategies for the use of nonstatin therapies. <i>Current Opinion in Lipidology</i> , 2017, 28, 458-464.	2.7	2
238	Differential contribution of PCSK9 and LPL gene variants on lipid profile in the general population. <i>Atherosclerosis</i> , 2017, 263, e66.	0.8	0
239	Effect of PCSK9 loss-of-function mutation R46I on plasma lipids, endothelial function and vascular inflammation in the post-prandial state. <i>Atherosclerosis</i> , 2017, 263, e136.	0.8	0
240	Clinical significance of diabetes likely induced by statins: Evidence from a large population-based cohort. <i>Diabetes Research and Clinical Practice</i> , 2017, 133, 60-68.	2.8	15
241	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above. <i>Circulation</i> , 2017, 136, 1878-1891.	1.6	144
242	PCSK9 inhibition in statin-intolerant HeFH patients: What's new?. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1525-1527.	1.8	0
243	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 419-431.	2.6	45
244	PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1870-1877.	1.8	55
245	Characterization of Italian patients with familial hypercholesterolemia: The lipigen study. <i>Atherosclerosis</i> , 2017, 263, e235.	0.8	0
246	Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. <i>Atherosclerosis</i> , 2017, 263, e262-e263.	0.8	4
247	Ldl-cholesterol reduction with PCSK9 inhibitors: A meta-analysis of randomised controlled trials. <i>Atherosclerosis</i> , 2017, 263, e244.	0.8	1
248	Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. <i>Immunity</i> , 2017, 47, 875-889.e10.	14.3	181
249	Automatic identification of variables in epidemiological datasets using logic regression. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 40.	3.0	2
250	Corrigendum to "Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database" [Diabetes Res. Clin. Pract. 108 (2) (2015) 243-249]. <i>Diabetes Research and Clinical Practice</i> , 2017, 125, 68.	2.8	0
251	Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?. <i>Drug Discovery Today</i> , 2017, 22, 85-96.	6.4	64
252	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 947.	7.4	247

#	ARTICLE	IF	CITATIONS
253	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. Journal of the American College of Cardiology, 2017, 70, 1290-1301.	2.8	162
254	Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. Vascular Health and Risk Management, 2017, Volume 13, 343-351.	2.3	14
255	Current guidelines on prevention with a focus on dyslipidemias. Cardiovascular Diagnosis and Therapy, 2017, 67, S4-S10.	1.7	13
256	Advances in Hypercholesterolemia. , 2017, , 663-693.		1
257	World Heart Federation Cholesterol Roadmap. Global Heart, 2017, 12, 179.	2.3	30
258	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnosticâ€therapeutic pathway in Italy. European Heart Journal Supplements, 2017, 19, D3-D54.	0.1	19
259	2016 ESC/EAS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDAEMIAS. Russian Journal of Cardiology, 2017, , 7-77.	1.4	15
260	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0162473.	2.5	41
261	Variation in<i>PCSK9</i>and<i>HMGCR</i>and Risk of Cardiovascular Disease and Diabetes. New England Journal of Medicine, 2016, 375, 2144-2153.	27.0	596
262	SAT0302â€...Active Systemic Lupus Erythematosus Associates with Carotid Intima-Media Thickness Progression. Annals of the Rheumatic Diseases, 2016, 75, 777.2-777.	0.9	0
263	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis Supplements, 2016, 22, 1-32.	1.2	90
264	Identification of Statin Intolerance: Results From A Survey of Clinicians in Taiwan. Value in Health, 2016, 19, A872.	0.3	0
265	Identification of Statin Intolerance: Results from a Survey of Clinicians in Six European Countries. Value in Health, 2016, 19, A664.	0.3	0
266	Identification and Management of Patients with Statin Intolerance in Saudi Arabia and the United Arab Emirates: Comparison of Results from a Clinician Survey. Value in Health, 2016, 19, A664.	0.3	0
267	Identification of Statin Intolerance: Results From A Survey of South Korean Clinicians. Value in Health, 2016, 19, A872.	0.3	0
268	Management of Patients with Statin Intolerance in Japan, South Korea and Taiwan: Comparison of Results From A Clinician Survey. Value in Health, 2016, 19, A872.	0.3	1
269	Identification of Statin Intolerance: Results From a Survey of Clinicians in Japan. Value in Health, 2016, 19, A872-A873.	0.3	0
270	Management of Patients with Statin Intolerance: Results from a Survey of Clinicians in Six European Countries. Value in Health, 2016, 19, A664.	0.3	0

#	ARTICLE	IF	CITATIONS
271	A simple informative intervention in primary care increases statin adherence. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 227-234.	1.9	5
272	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2016, 37, 2315-2381.	2.2	5,370
273	Identification and Management of Canadian Patients with Symptoms of Statin Intolerance: Results from a Real-World Clinical Practice Survey. <i>Value in Health</i> , 2016, 19, A53.	0.3	0
274	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016, 18, C2-C12.	0.1	71
275	Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 1182-1190.	3.8	32
276	Residual cardiovascular risk. <i>European Heart Journal Supplements</i> , 2016, 18, C1-C1.	0.1	8
277	Impact of substitution among generic drugs on persistence and adherence: A retrospective claims data study from 2 Local Healthcare Units in the Lombardy Region of Italy. <i>Atherosclerosis Supplements</i> , 2016, 21, 1-8.	1.2	19
278	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>Atherosclerosis</i> , 2016, 253, 281-344.	0.8	1,189
279	Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2016, 118, 1812-1820.	1.6	7
280	Pentraxin 3 deficiency is associated with increased arterial thrombosis in animal models. <i>Atherosclerosis</i> , 2016, 252, e250-e251.	0.8	0
281	Leukocyte telomere length, genetically determined, is causally associated with the progression of carotid Intima-Media Thickness and incidence of cardiovascular events. <i>Atherosclerosis</i> , 2016, 252, e252.	0.8	2
282	Systemic lupus erythematosus flare-up is associated with increased 5-years carotid Intima-Media thickness progression. <i>Atherosclerosis</i> , 2016, 252, e169.	0.8	0
283	GPER p.P16L polymorphism is not associated with altered lipid phenotypes and cimt progression â€” A PLIC study. <i>Atherosclerosis</i> , 2016, 252, e76.	0.8	1
284	Identifying and Managing Patients with Symptoms of Statin Intolerance: Results from a Survey of Clinicians in the United States. <i>Value in Health</i> , 2016, 19, A53.	0.3	0
285	PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. <i>Atherosclerosis</i> , 2016, 253, 214-224.	0.8	78
286	Reply to: â€œStatins probably do not cause cataractsâ€. <i>Atherosclerosis</i> , 2016, 254, 311-312.	0.8	0
287	Circulating CD14+ and CD14highCD16â” classical monocytes are reduced in patients with signs of plaque neovascularization in the carotid artery. <i>Atherosclerosis</i> , 2016, 255, 171-178.	0.8	32
288	Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. <i>Cardiovascular Research</i> , 2016, 112, 429-442.	3.8	105

#	ARTICLE	IF	CITATIONS
289	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 2016, 37, 2999-3058.	2.2	2,393
290	Genetically determined telomeres shortening is associated with carotid atherosclerosis progression and increased incidence of cardiovascular events. International Journal of Cardiology, 2016, 223, 43-45.	1.7	2
291	2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis, 2016, 252, 207-274.	0.8	415
292	Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice. Atherosclerosis, 2016, 252, 1-8.	0.8	26
293	Role of PCSK9 (proprotein convertase subtilisin/kexin type 9) in obesity and metabolic syndrome: Beyond LDLR targeting. Atherosclerosis, 2016, 252, e223.	0.8	0
294	Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia. Atherosclerosis, 2016, 254, 172-178.	0.8	13
295	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Scientific Reports, 2016, 6, 30060.	3.3	25
296	Statin use and risk of cataract: A nested case-control study within a healthcare database. Atherosclerosis, 2016, 251, 153-158.	0.8	20
297	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes and Endocrinology, the, 2016, 4, 850-861.	11.4	329
298	Identification and Management of Patients with Symptoms of Statin Intolerance: Results from A Survey of Brazilian Clinicians. Value in Health, 2016, 19, A53.	0.3	0
299	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2016, 23, NP1-NP96.	1.8	683
300	Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. European Journal of Preventive Cardiology, 2016, 23, 194-205.	1.8	74
301	Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey. Atherosclerosis, 2016, 245, 111-117.	0.8	57
302	Normative values for carotid intima media thickness and its progression: Are they transferrable outside of their cohort of origin?. European Journal of Preventive Cardiology, 2016, 23, 1165-1173.	1.8	33
303	Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 141-153.	2.6	42
304	Comparison of <sc>PCSK9</sc> Inhibitor Evolocumab vs Ezetimibe in Statinâ€ntolerant Patients: Design of the Goal Achievement After Utilizing an Antiâ€<sc>PCSK9</sc> Antibody in Statinâ€ntolerant Subjects 3 (<sc>GAUSS</sc>â€3) Trial. Clinical Cardiology, 2016, 39, 137-144.	1.8	32
305	Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10Âyears of follow-up. Atherosclerosis, 2016, 246, 208-213.	0.8	78
306	Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases. Current Medicinal Chemistry, 2016, 23, 983-999.	2.4	29

#	ARTICLE	IF	CITATIONS
307	Epicardial and liver fat, evaluated by ultrasound in general population and in non-alcoholic fatty liver disease (NAFLD) predict cardiovascular damage. Digestive and Liver Disease, 2015, 47, e223.	0.9	0
308	Real-World Identification Of European Patients With Statin-Associated Symptoms: Clinical Practice Compared With Clinical Guidelines. Value in Health, 2015, 18, A401.	0.3	0
309	Medication persistence and the use of generic and brand-name blood pressure-lowering agents. Journal of Hypertension, 2015, 33, 2181.	0.5	0
310	Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. Thrombosis and Haemostasis, 2015, 114, 186-197.	3.4	21
311	IDOL N342S Variant, Atherosclerosis Progression and Cardiovascular Disorders in the Italian General Population. PLoS ONE, 2015, 10, e0122414.	2.5	10
312	An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. Journal of Experimental Medicine, 2015, 212, 905-925.	8.5	128
313	Statin-associated muscle symptoms: impact on statin therapy”European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 2015, 36, 1012-1022.	2.2	1,024
314	Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 689-699.	2.4	165
315	Managing Patients With Statin-Associated Symptoms: Does Real-World Clinical Practice Align With Clinical Guidelines And Hta Recommendations In Europe?. Value in Health, 2015, 18, A401.	0.3	0
316	Drug interactions in pharmacovigilance. Toxicology Letters, 2015, 238, S28-S29.	0.8	0
317	Think Again About Cholesterol Survey. Atherosclerosis Supplements, 2015, 20, 1-5.	1.2	10
318	Telomere shortening over 6Âyears is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population. Journal of Internal Medicine, 2015, 277, 478-487.	6.0	49
319	Introduction. Atherosclerosis Supplements, 2015, 17, 1.	1.2	1
320	Homozygous familial hypobetalipoproteinemia: Two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature. Atherosclerosis, 2015, 239, 209-217.	0.8	17
321	Identification of two novel mutations of the LDL receptorÂgene in two Italian families with familial hypercholesterolemia. Atherosclerosis, 2015, 241, e114.	0.8	0
322	Apolipoprotein E in humans and mice impacts the differentiation of naive CD4 T cells toward effector subsets. Atherosclerosis, 2015, 241, e7.	0.8	0
323	Epicardial fat thickness is an ectopic fat associated with metabolic syndrome, subclinical atherosclerosis and markers of cardiac dysfunction in the general population. Atherosclerosis, 2015, 241, e47.	0.8	0
324	Carotid Intima-Media Thickness Progression and Risk of Vascular Events in People With Diabetes: Results From the PROG-IMT Collaboration. Diabetes Care, 2015, 38, 1921-1929.	8.6	67

#	ARTICLE	IF	CITATIONS
325	IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease. <i>Atherosclerosis</i> , 2015, 241, 498-501.	0.8	26
326	Statin Intolerance: Diagnosis and Remedies. <i>Current Cardiology Reports</i> , 2015, 17, 27.	2.9	32
327	Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2129.	4.3	12
328	Statins use and the risk of all and subtype hematological malignancies: a meta-analysis of observational studies. <i>Cancer Medicine</i> , 2015, 4, 770-780.	2.8	28
329	Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, 243-249.	2.8	9
330	Apolipoprotein C-III: From Pathophysiology to Pharmacology. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 675-687.	8.7	144
331	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. <i>European Heart Journal</i> , 2015, 36, 2425-2437.	2.2	644
332	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015, 243, 257-259.	0.8	148
333	Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From inÂvitro evidence to clinical studies. <i>Atherosclerosis</i> , 2015, 243, 449-461.	0.8	231
334	A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate"statin combination therapy. <i>Atherosclerosis Supplements</i> , 2015, 19, 1-12.	1.2	66
335	Functional Analysis of a Carotid Intima-Media Thickness Locus Implicates <i>BCAR1</i> and Suggests a Causal Variant. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 696-706.	5.1	17
336	Corrigendum to "Statins decrease thrombin generation in patients with hypercholesterolemia"[<i>Eur J Intern Med</i> 25(5), 449-451]. <i>European Journal of Internal Medicine</i> , 2015, 26, 460.	2.2	0
337	HDL in Infectious Diseases and Sepsis. <i>Handbook of Experimental Pharmacology</i> , 2015, 224, 483-508.	1.8	145
338	Statins and Lomitapide: A Suitable Response for Homozygous Familial Hypercholesterolemia?. , 2015, , 87-97.		2
339	An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. <i>Journal of Cell Biology</i> , 2015, 209, 2094-2103.	5.2	0
340	Postprandial lipemia as a cardiometabolic risk factor. <i>Current Medical Research and Opinion</i> , 2014, 30, 1489-1503.	1.9	94
341	HDL in innate and adaptive immunity. <i>Cardiovascular Research</i> , 2014, 103, 372-383.	3.8	236
342	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157.	2.2	835

#	ARTICLE	IF	CITATIONS
343	The Arachidonic Acid Metabolome Serves as a Conserved Regulator of Cholesterol Metabolism. <i>Cell Metabolism</i> , 2014, 20, 787-798.	16.2	92
344	High-potency statins increase the risk of acute kidney injury: Evidence from a large population-based study. <i>Atherosclerosis</i> , 2014, 234, 224-229.	0.8	19
345	Corrigendum to “Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials” [Atheroscler Suppl 14 (2) (2013) 243-251]. <i>Atherosclerosis</i> , 2014, 233, 122.	0.8	4
346	The CD1d-Natural Killer T Cell Axis in Atherosclerosis. <i>Journal of Innate Immunity</i> , 2014, 6, 3-12.	3.8	20
347	15-Lipoxygenase-Mediated Modification of HDL ³ Impairs eNOS Activation in Human Endothelial Cells. <i>Lipids</i> , 2014, 49, 317-326.	1.7	9
348	Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States. <i>Contemporary Diabetes</i> , 2014, , 125-139.	0.0	2
349	Comment to the position paper on global recommendations for the management of dyslipidemia developed by the International Atherosclerosis Society (IAS). <i>Atherosclerosis</i> , 2014, 233, 508-509.	0.8	2
350	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. <i>European Heart Journal</i> , 2014, 35, 960-968.	2.2	270
351	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. <i>Atherosclerosis</i> , 2014, 232, 346-360.	0.8	419
352	Statins and periodontal inflammation: A pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?. <i>Atherosclerosis</i> , 2014, 234, 381-382.	0.8	3
353	Statins and skeletal muscles toxicity: From clinical trials to everyday practice. <i>Pharmacological Research</i> , 2014, 88, 107-113.	7.1	48
354	Progression of early atherosclerotic vascular damage in patients with NAFLD and in controls of general population during 10 years of follow up. <i>Digestive and Liver Disease</i> , 2014, 46, e26.	0.9	0
355	Combination therapy in dyslipidemia: Where are we now?. <i>Atherosclerosis</i> , 2014, 237, 319-335.	0.8	39
356	Targeting PCSK9 for Hypercholesterolemia. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 273-293.	9.4	96
357	Novel concepts in HDL pharmacology. <i>Cardiovascular Research</i> , 2014, 103, 423-428.	3.8	31
358	HDL: To Treat or Not To Treat?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 429.	4.8	12
359	Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. <i>European Heart Journal</i> , 2014, 35, 1996-2000.	2.2	34
360	Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. <i>European Journal of Internal Medicine</i> , 2014, 25, 745-750.	2.2	37

#	ARTICLE	IF	CITATIONS
361	Concluding comments. Atherosclerosis Supplements, 2014, 15, 52.	1.2	0
362	Statins and the Risk of Diabetes: Evidence From a Large Population-Based Cohort Study. Diabetes Care, 2014, 37, 2225-2232.	8.6	83
363	New strategies for the management of patients with homozygous familial hypercholesterolaemia. Atherosclerosis Supplements, 2014, 15, 17-18.	1.2	0
364	Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 518-523.	2.6	31
365	Epicardial fat thickness (EAT) in patients with nonalcoholic fatty liver disease (NAFLD) is associated with markers of cardiovascular damage and severity of steatosis. Digestive and Liver Disease, 2014, 46, e3-e4.	0.9	0
366	Lower incidence of macrovascular complications in patients on insulin glargine versus those on basal human insulins: A population-based cohort study in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 10-17.	2.6	30
367	Statins decrease thrombin generation in patients with hypercholesterolemia. European Journal of Internal Medicine, 2014, 25, 449-451.	2.2	14
368	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes and Endocrinology, 2014, 2, 655-666.	11.4	473
369	PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges. Vascular Pharmacology, 2014, 62, 103-111.	2.1	30
370	Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 751-759.	2.6	39
371	MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr ^{-/-} mice. Thrombosis and Haemostasis, 2014, 112, 796-802.	3.4	87
372	Medication persistence and the use of generic and brand-name blood pressure-lowering agents. Journal of Hypertension, 2014, 32, 1146-1153.	0.5	30
373	Plasma proprotein convertase subtilisin kexin type 9 (pcsk9) and plasma lipids in a free living population: results from the plic study. Atherosclerosis, 2014, 235, e60.	0.8	1
374	Proprotein convertase subtilisin/kexin type 9 deficient mice are protected from neointima formation in carotid artery injury model. Atherosclerosis, 2014, 235, e21-e22.	0.8	0
375	Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. European Journal of Clinical Pharmacology, 2013, 69, 341-346.	1.9	23
376	Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. Atherosclerosis Supplements, 2013, 14, 237-242.	1.2	27
377	Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials. Atherosclerosis Supplements, 2013, 14, 243-251.	1.2	131
378	In Memoriam. Obituary: Professor Andrea Mezzetti, MD (1949-2013). Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 903-904.	2.6	0

#	ARTICLE	IF	CITATIONS
379	Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia. International Journal of Cardiology, 2013, 170, S16-S20.	1.7	32
380	New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. European Heart Journal, 2013, 34, 1783-1789.	2.2	90
381	Abdominal visceral fat measurement using dual-energy X-ray: Association with cardiometabolic risk factors. Obesity, 2013, 21, 1798-1802.	3.0	58
382	Three-Year Health Care Expenditures in Diabetic Patients Receiving Rapid-Acting Insulin Analogues Versus Those on Human Regular Insulin. Value in Health, 2013, 16, A451.	0.3	0
383	The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis, 2013, 228, 18-28.	0.8	119
384	Long-term use of statins reduces the risk of hospitalization for dementia. Atherosclerosis, 2013, 230, 171-176.	0.8	35
385	Different patterns characterize Omega 6 and Omega 3 long chain polyunsaturated fatty acid levels in blood from Italian infants, children, adults and elderly. Prostaglandins Leukotrienes and Essential Fatty Acids, 2013, 89, 215-220.	2.2	24
386	C-reactive protein distribution and correlation with traditional cardiovascular risk factors in the Italian population. European Journal of Internal Medicine, 2013, 24, 161-166.	2.2	4
387	Prevalence of classical CD14 ⁺⁺ /CD16 ⁺ but not of intermediate CD14 ⁺⁺ /CD16 ⁺ monocytes in hypoalphalipoproteinemia. International Journal of Cardiology, 2013, 168, 2886-2889.	1.7	15
388	High-Density Lipoprotein Subfractions - What the Clinicians Need to Know. Cardiology, 2013, 124, 116-125.	1.4	509
389	Gene silencing approaches for the management of dyslipidaemia. Trends in Pharmacological Sciences, 2013, 34, 198-205.	8.7	29
390	Guidelines on CVD prevention: Confusing or complementary?. Atherosclerosis, 2013, 226, 299-300.	0.8	5
391	MicroRNAs and lipoproteins: A connection beyond atherosclerosis?. Atherosclerosis, 2013, 227, 209-215.	0.8	36
392	Identification of seven loci affecting mean telomere length and their association with disease. Nature Genetics, 2013, 45, 422-427.	21.4	808
393	Moderate alcohol use and health: A consensus document. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 487-504.	2.6	120
394	-374 T/A RAGE Polymorphism Is Associated with Chronic Kidney Disease Progression in Subjects Affected by Nephrocardiovascular Disease. PLoS ONE, 2013, 8, e60089.	2.5	11
395	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal, 2013, 34, 3478-3490.	2.2	2,132
396	LOX-1, OxLDL, and Atherosclerosis. Mediators of Inflammation, 2013, 2013, 1-12.	3.0	548

#	ARTICLE	IF	CITATIONS
397	Soluble Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 as a Biochemical Marker for Atherosclerosis-Related Diseases. Disease Markers, 2013, 35, 413-418.	1.3	60
398	Long Pentraxin 3: Experimental and Clinical Relevance in Cardiovascular Diseases. Mediators of Inflammation, 2013, 2013, 1-10.	3.0	89
399	Guidelines on CVD prevention: confusing or complementary?. European Journal of Preventive Cardiology, 2013, 20, 6-8.	1.8	2
400	The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. Clinical Lipidology, 2013, 8, 13-41.	0.4	23
401	Statins and primary liver cancer. European Journal of Cancer Prevention, 2013, 22, 229-234.	1.3	70
402	High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. Journal of Internal Medicine, 2013, 274, 252-262.	6.0	68
403	Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Tj ETQq1 1 0.784314 rgBT ₀ /Overlook	1.9	
404	Class II Phosphoinositide 3-Kinases Contribute to Endothelial Cells Morphogenesis. PLoS ONE, 2013, 8, e53808.	2.5	23
405	Prevalence of the Prescription of Potentially Interacting Drugs. PLoS ONE, 2013, 8, e78827.	2.5	41
406	Lower Rate of Cardiovascular Complications in Patients on Bolus Insulin Analogues: A Retrospective Population-Based Cohort Study. PLoS ONE, 2013, 8, e79762.	2.5	9
407	Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality. Current Pharmaceutical Design, 2013, 19, 3841-3857.	1.9	27
408	High density lipoproteins and atherosclerosis: emerging aspects. Journal of Geriatric Cardiology, 2013, 9, 401-407.	0.2	20
409	Adherence to lipid-lowering treatment: the patient perspective. Patient Preference and Adherence, 2012, 6, 805.	1.8	43
410	Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis. Oncologist, 2012, 17, 813-822.	3.7	233
411	LOX-1 Inhibition in ApoE KO Mice Using a Schizophyllan-based Antisense Oligonucleotide Therapy. Molecular Therapy - Nucleic Acids, 2012, 1, e58.	5.1	11
412	Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. Journal of the American Heart Association, 2012, 1, 27-41.	3.7	114
413	Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis, with Particular Reference to Pitavastatin. Current Vascular Pharmacology, 2012, 10, 257-267.	1.7	44
414	Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation. Journal of Hypertension, 2012, 30, 1056-1064.	0.5	86

#	ARTICLE	IF	CITATIONS
415	Microrna 143â€“145 Deficiency Impairs Vascular Function. International Journal of Immunopathology and Pharmacology, 2012, 25, 467-474.	2.1	29
416	Pitavastatin: a different pharmacological profile. Clinical Lipidology, 2012, 7, 3-9.	0.4	13
417	Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet, The, 2012, 379, 2053-2062.	13.7	506
418	Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis, 2012, 220, 11-21.	0.8	158
419	Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis, 2012, 220, 381-386.	0.8	212
420	Leonurine: A new comer in the natural compounds affecting atherosclerosis. Atherosclerosis, 2012, 224, 37-38.	0.8	9
421	HDL and adaptive immunity: A tale of lipid rafts. Atherosclerosis, 2012, 225, 34-35.	0.8	21
422	PDB11 A Large-Scale Longitudinal Population-Based Study of Risk Reduction of Cardiovascular Complications in Patients on Bolus Insulin Analogues. Value in Health, 2012, 15, A495.	0.3	0
423	How many patients need statin treatment in a low-cardiovascular-risk country? Low-density lipoprotein-cholesterol target and distance from target distribution in an Italian cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 327-336.	2.6	13
424	Effect of Tie-2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 927-935.	3.8	9
425	Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins. Biochemical and Biophysical Research Communications, 2012, 428, 230-233.	2.1	23
426	Association between OLR1 K167N SNP and Intima Media Thickness of the Common Carotid Artery in the General Population. PLoS ONE, 2012, 7, e31086.	2.5	21
427	Effect of a long-term oral L-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism, 2012, 14, 893-900.	4.4	58
428	Association between the Adherence to AHA Step 1 Nutrition Criteria and the Cardiometabolic Outcome in the General Population a Two Year Follow-Up Study. Food and Nutrition Sciences (Print), 2012, 03, 274-280.	0.4	1
429	Risk factors distribution and cardiovascular disease prevalence in the Italian population: The CHECK study. Open Journal of Epidemiology, 2012, 02, 90-100.	0.4	3
430	Pentraxins and Atherosclerosis. , 2012, , 219-237.		0
431	Novel biotinylated bile acid amphiphiles: Micellar aggregates formation and interaction with hepatocytes. Organic and Biomolecular Chemistry, 2011, 9, 2899.	2.8	0
432	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal, 2011, 32, 1345-1361.	2.2	993

#	ARTICLE	IF	CITATIONS
433	Reaching LDL-c targets in high-risk patients requires high-efficacy cholesterol-lowering drugs in more than 50% of cases. The results of the CHECK study. <i>Pharmacological Research</i> , 2011, 64, 393-396.	7.1	14
434	Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure to function relation to therapeutic inhibition. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 835-843.	2.6	95
435	Corrigendum to "Treatment of diabetic ulcers, using autologous platelet and fibrin gel. Experience with the FIBRINETÂ® device" [Transf. Aphere. Sci. 43 (2010) 171-172]. <i>Transfusion and Apheresis Science</i> , 2011, 44, 107.	1.0	0
436	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	2.2	2,767
437	Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. <i>Atherosclerosis</i> , 2011, 214, 331-337.	0.8	36
438	Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. <i>Atherosclerosis</i> , 2011, 217, 479-485.	0.8	26
439	The new joint EAS/ESC guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 1.	0.8	92
440	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 1-44.	0.8	180
441	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 3-46.	0.8	561
442	Therapy and clinical trials. <i>Current Opinion in Lipidology</i> , 2011, 22, 324-325.	2.7	1
443	HDLs, immunity, and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2011, 22, 410-416.	2.7	41
444	Endothelin-1 does not impair insulin-induced angiogenesis in vitro. <i>International Journal of Molecular Medicine</i> , 2011, 28, 443-8.	4.0	1
445	Therapy and clinical trials: new insights. <i>Current Opinion in Lipidology</i> , 2010, 21, 394-395.	2.7	0
446	Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. <i>Current Opinion in Lipidology</i> , 2010, 21, 492-498.	2.7	95
447	Lecithin:cholesterol acyltransferase and vascular disease. <i>Clinical Lipidology</i> , 2010, 5, 13-15.	0.4	0
448	Blood pressure and antihypertensive therapy according to the global cardiovascular risk level in Italy: the CHECK Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 562-568.	2.8	4
449	The Long Pentraxin PTX3: A Modulator of the Immunoinflammatory Response in Atherosclerosis and Cardiovascular Diseases. <i>Trends in Cardiovascular Medicine</i> , 2010, 20, 35-40.	4.9	136
450	Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. <i>Clinical Therapeutics</i> , 2010, 32, 300-310.	2.5	76

#	ARTICLE	IF	CITATIONS
451	From endothelial dysfunction to atherosclerosis. <i>Autoimmunity Reviews</i> , 2010, 9, 830-834.	5.8	432
452	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010, 31, 2844-2853.	2.2	1,392
453	Circulating CD4 ⁺ CD25 ^{hi} CD127 ^{lo} Regulatory T-Cell Levels Do Not Reflect the Extent or Severity of Carotid and Coronary Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1832-1841.	2.4	125
454	Update on the efficacy and safety of combination ezetimibe plus statin therapy. <i>Clinical Lipidology</i> , 2010, 5, 655-684.	0.4	33
455	Barriers to cardiovascular disease risk scoring and primary prevention in Europe. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2010, 103, 727-739.	0.5	80
456	Dual effect of hypochlorite in the modification of high density lipoproteins. <i>Biochemical and Biophysical Research Communications</i> , 2010, 403, 447-451.	2.1	10
457	Plasma adiponectin levels in chronic kidney disease patients: Relation with molecular inflammatory profile and metabolic status. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 56-63.	2.6	29
458	Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): Rationale and design of a meta-analysis project. <i>American Heart Journal</i> , 2010, 159, 730-736.e2.	2.7	37
459	Pitavastatin α pharmacological profile from early phase studies. <i>Atherosclerosis Supplements</i> , 2010, 11, 3-7.	1.2	37
460	Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. <i>Atherosclerosis</i> , 2010, 208, 177-182.	0.8	74
461	Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. <i>Atherosclerosis</i> , 2010, 210, 78-87.	0.8	48
462	The androgen derivative 5 α -androstane-3 β ,17 β -diol inhibits tumor necrosis factor α and lipopolysaccharide induced inflammatory response in human endothelial cells and in mice aorta. <i>Atherosclerosis</i> , 2010, 212, 100-106.	0.8	37
463	Perspectives on low-density lipoprotein cholesterol goal achievement. <i>Current Medical Research and Opinion</i> , 2009, 25, 431-447.	1.9	39
464	Deficiency of the Long Pentraxin PTX3 Promotes Vascular Inflammation and Atherosclerosis. <i>Circulation</i> , 2009, 120, 699-708.	1.6	252
465	Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 129-134.	2.6	94
466	Oral l-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aortocoronary bypass. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1270-1276.	3.4	91
467	Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk Category. <i>Metabolic Syndrome and Related Disorders</i> . 2009, 7, 601-610.	1.3	9
468	Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. <i>Atherosclerosis</i> , 2009, 206, 556-562.	0.8	69

#	ARTICLE	IF	CITATIONS
469	Bridging science and health policy in cardiovascular disease: focus on lipid management. <i>Atherosclerosis Supplements</i> , 2009, 10, 3-21.	1.2	10
470	Cholesterol Absorption Inhibitors. , 2009, , 288-297.		0
471	Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. <i>Journal of Clinical Lipidology</i> , 2008, 2, 91-105.	1.5	22
472	Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. <i>Journal of Clinical Lipidology</i> , 2008, 2, 436-446.	1.5	13
473	Carotid Artery Intima-media Thickness in Nonalcoholic Fatty Liver Disease. <i>American Journal of Medicine</i> , 2008, 121, 72-78.	1.5	189
474	Non-pharmacological control of plasma cholesterol levels. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, S1-S16.	2.6	52
475	LDL-C REDUCTION AND GOAL ACHIEVEMENT IN PATIENTS WITH DIABETES, METABOLIC SYNDROME, OR NEITHER DISEASE, STRATIFIED BY NCEP CHD RISK CATEGORY. <i>Atherosclerosis Supplements</i> , 2008, 9, 73.	1.2	0
476	Side Effects of Anabolic Androgenic Steroids Abuse. <i>International Journal of Sports Medicine</i> , 2008, 29, 679-687.	1.7	96
477	The 15-Lipoxygenase-Modified High Density Lipoproteins 3 Fail to Inhibit the TNF- α -Induced Inflammatory Response in Human Endothelial Cells. <i>Journal of Immunology</i> , 2008, 181, 2821-2830.	0.8	24
478	Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 925-931.	2.4	137
479	Response to Letter by Kotani et al. <i>Stroke</i> , 2008, 39, .	2.0	0
480	Combination therapy in cholesterol reduction: focus on ezetimibe and statins. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 267-278.	2.3	21
481	Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux. <i>Cardiovascular Research</i> , 2007, 75, 566-574.	3.8	18
482	Improvement of endothelial function in uraemic patients on peritoneal dialysis: a possible role for 5-MTHF administration. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3292-3297.	0.7	17
483	Leptin:Adiponectin Ratio Is an Independent Predictor of Intima Media Thickness of the Common Carotid Artery. <i>Stroke</i> , 2007, 38, 2844-2846.	2.0	164
484	Plasma resistin levels correlate with determinants of the metabolic syndrome. <i>European Journal of Endocrinology</i> , 2007, 156, 279-284.	3.7	176
485	Triglyceride-Rich Lipoproteins From Normotriglyceridemic Subjects and Hyperlipidemic Patients Differently Affect Endothelial Cell Activation and Gene Expression Patterns. <i>Circulation Research</i> , 2007, 100, e81.	4.5	9
486	Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007, 14, 340-345.	2.8	0

#	ARTICLE	IF	CITATIONS
487	Triglyceride-rich lipoproteins and endothelial dysfunction: molecular mechanisms and gene expression studies. <i>Future Lipidology</i> , 2007, 2, 119-122.	0.5	0
488	ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE-KO mice. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 543-548.	2.1	5
489	Anti-inflammatory and anti-atherogenic effects of catechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. <i>Atherosclerosis</i> , 2007, 191, 265-271.	0.8	131
490	Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: Molecular mechanisms and gene expression studies. <i>Atherosclerosis</i> , 2007, 193, 321-327.	0.8	122
491	Molecular Mechanisms Responsible for the Anti-Inflammatory and Protective Effect of High-Density Lipoprotein on the Endothelium. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 21-31.	2.2	2
492	Genetic Polymorphisms in an Aged Population. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 99-101.	2.2	1
493	Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. <i>Current Medical Research and Opinion</i> , 2007, 23, 2009-2026.	1.9	146
494	Inhibition of synthesis and absorption of cholesterol: A new option in managing hypercholesterolemia. <i>International Congress Series</i> , 2007, 1303, 121-128.	0.2	1
495	ASSET (Age/Sex Standardised Estimates of Treatment): A Research Model to Improve the Governance of Prescribing Funds in Italy. <i>PLoS ONE</i> , 2007, 2, e592.	2.5	13
496	Monitoring statin safety in primary care. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 652-657.	1.9	8
497	Effect of the ?420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. <i>Journal of Internal Medicine</i> , 2007, 262, 104-112.	6.0	60
498	The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balance. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 21-26.	1.9	6
499	Averting a pandemic health crisis in Europe by 2020: what physicians need to know regarding cholesterol management. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007, 14, 340-345.	2.8	2
500	Th-P15:199 Modulation of pentraxin 3 expression in endothelial cells: Role of HDL. <i>Atherosclerosis Supplements</i> , 2006, 7, 537.	1.2	0
501	Synthesis and Biological Evaluation of Azido- and Aziridino-hydroxyl- β -lactams through Stereo- and Regioselective Epoxide Ring Opening. <i>Journal of Organic Chemistry</i> , 2006, 71, 9229-9232.	3.2	15
502	15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2006, 1761, 292-300.	2.4	34
503	Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a pro-inflammatory response in the endothelium: Molecular mechanisms and gene expression studies. <i>Journal of Molecular and Cellular Cardiology</i> , 2006, 40, 484-494.	1.9	55
504	Modified HDL: Biological and physiopathological consequences. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 371-386.	2.6	75

#	ARTICLE	IF	CITATIONS
505	Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. International Journal of Molecular Medicine, 2006, 18, 209.	4.0	7
506	HDL and endothelial function: from molecular mechanisms to clinical observations. Future Lipidology, 2006, 1, 343-355.	0.5	3
507	Secondary prevention of myocardial infarction: a survey in primary care. Journal of Cardiovascular Medicine, 2006, 7, 422-426.	1.5	1
508	In Human Endothelial Cells Amino Acids Inhibit Insulin-induced Akt and ERK1/2 Phosphorylation by an mTOR-dependent Mechanism. Journal of Cardiovascular Pharmacology, 2006, 47, 643-649.	1.9	11
509	Dihydrotestosterone Decreases Tumor Necrosis Factor- α and Lipopolysaccharide-Induced Inflammatory Response in Human Endothelial Cells. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 546-554.	3.6	139
510	Role of Vitamin E-Coated Membrane in Reducing Advanced Glycation End Products in Hemodialysis Patients: A Pilot Study. Blood Purification, 2006, 24, 369-376.	1.8	40
511	Effects of Fractalkine Receptor Variants on Common Carotid Artery Intima-Media Thickness. Stroke, 2006, 37, 1558-1561.	2.0	48
512	Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Current Medical Research and Opinion, 2006, 22, 2041-2053.	1.9	101
513	In vitro isolation of circulating endothelial progenitor cells is related to the high density lipoprotein plasma levels. International Journal of Molecular Medicine, 2006, 17, 203-8.	4.0	27
514	Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. International Journal of Molecular Medicine, 2006, 18, 209-13.	4.0	11
515	Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. Journal of Internal Medicine, 2005, 258, 21-27.	6.0	74
516	Acute Effect of High-Fat Meal on Endothelial Function in Moderately Dyslipidemic Subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 406-410.	2.4	67
517	High-Density Lipoproteins Induce Transforming Growth Factor- β 2 Expression in Endothelial Cells. Circulation, 2005, 111, 2805-2811.	1.6	84
518	Inherited Apolipoprotein A-V Deficiency in Severe Hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 411-417.	2.4	177
519	Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 159-163.	2.8	3
520	MTE01-IS-003 LCAT deficiency. Atherosclerosis Supplements, 2005, 6, 181.	1.2	0
521	Global Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 125-133.	2.2	0
522	Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Current Medical Research and Opinion, 2005, 21, 1123-1130.	1.9	42

#	ARTICLE	IF	CITATIONS
523	Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 159-163.	2.8	2
524	Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. <i>Vascular Health and Risk Management</i> , 2005, 1, 119-129.	2.3	63
525	Targeting Two Sources of Cholesterol “An Advanced Treatment Approach to Lipid-lowering Management. <i>European Cardiology Review</i> , 2005, 1, 1.	2.2	0
526	Lipoprotein Remnants and Endothelial Dysfunction in the Postprandial Phase. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2946-2950.	3.6	69
527	Native LDL and Oxidized LDL modulate cyclooxygenase-2 expression in HUVECs through a p38-MAPK, NF- κ B, CRE dependent pathway and affect PGE2 synthesis. <i>International Journal of Molecular Medicine</i> , 2004, 14, 353-9.	4.0	15
528	HDL ₃ Induces Cyclooxygenase-2 Expression and Prostacyclin Release in Human Endothelial Cells Via a p38 MAPK/CRE-Dependent Pathway: Effects on COX-2/PGI-Synthase Coupling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 871-877.	2.4	92
529	Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. <i>British Journal of Haematology</i> , 2004, 127, 97-104.	2.5	53
530	Triglycerides rich lipoproteins and atherosclerosis: in vitro and in vivo studies. <i>International Congress Series</i> , 2004, 1262, 507-510.	0.2	1
531	High-density lipoprotein subfraction 3 decreases ADAMTS-1 expression induced by lipopolysaccharide and tumor necrosis factor- α in human endothelial cells. <i>Matrix Biology</i> , 2004, 22, 557-560.	3.6	32
532	Lipid lowering activity of drugs affecting cholesterol absorption. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004, 14, 42-51.	2.6	14
533	Apolipoprotein C-II deficiency presenting as a lipid encephalopathy in infancy. <i>Annals of Neurology</i> , 2003, 53, 807-810.	5.3	32
534	Statins and Oxidative Stress During Atherogenesis. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 181-189.	2.8	6
535	Heart Protection Study. <i>Lancet</i> , The, 2003, 361, 528.	13.7	3
536	Effect of a standardized grape seed extract on low-density lipoprotein susceptibility to oxidation in heavy smokers. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1250-1257.	3.4	95
537	Effects of an Automated Electronic Reminder in Changing the Antiplatelet Drug-Prescribing Behavior Among Italian General Practitioners in Diabetic Patients: An intervention trial. <i>Diabetes Care</i> , 2003, 26, 1497-1500.	8.6	82
538	Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. <i>Cardiovascular Research</i> , 2003, 59, 169-180.	3.8	59
539	Effects of HDL3 on the expression of matrix-degrading proteases in human endothelial cells. <i>International Journal of Molecular Medicine</i> , 2003, 12, 73.	4.0	6
540	Title is missing!. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 153-154.	1.5	0

#	ARTICLE	IF	CITATIONS
541	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 181-189.	1.5	16
542	Effects of HDL3 on the expression of matrix-degrading proteases in human endothelial cells. International Journal of Molecular Medicine, 2003, 12, 73-8.	4.0	13
543	5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. Nephrology Dialysis Transplantation, 2002, 17, 857-864.	0.7	23
544	Novel statins: pharmacological and clinical results. Cardiovascular Drugs and Therapy, 2002, 16, 251-257.	2.6	30
545	Ezetimibe: a selective inhibitor of cholesterol absorption. European Heart Journal Supplements, 2001, 3, E6-E10.	0.1	50
546	Epitope mapping analysis of apolipoprotein B-100 using a surface plasmon resonance-based biosensor. Biosensors and Bioelectronics, 2001, 16, 963-969.	10.1	13
547	Overexpression of Inducible Heat Shock Protein 70 in COS-1 Cells Fails to Protect From Cytotoxicity of Oxidized LDLs. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 348-354.	2.4	18
548	Low density lipoprotein oxidation, antioxidants, and atherosclerosis. Current Opinion in Cardiology, 2000, 15, 355-363.	1.8	82
549	Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA. Gene Therapy, 2000, 7, 1795-1801.	4.5	22
550	Oxidized Lipoproteins and Endothelium. Clinical Chemistry and Laboratory Medicine, 2000, 38, 155-60.	2.3	16
551	Identification of domains in apoA-I susceptible to proteolysis by mast cell chymase: implications for HDL function. Journal of Lipid Research, 2000, 41, 975-984.	4.2	25
552	The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. Acta Diabetologica, 1999, 36, 27-33.	2.5	14
553	Antioxidants and coronary artery disease. Current Atherosclerosis Reports, 1999, 1, 221-229.	4.8	6
554	Oxysterols from oxidized LDL are cytotoxic but fail to induce hsp70 expression in endothelial cells. FEBS Letters, 1999, 462, 113-116.	2.8	11
555	NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. Atherosclerosis, 1999, 145, 87-95.	0.8	18
556	A successful dietary treatment fails to normalize plasma triglyceride postprandial response in type IV patients. Atherosclerosis, 1999, 146, 19-23.	0.8	6
557	TRIMETAZIDINE COUNTERACTS TACROLIMUS NEPHROTOXICITY IN A HYPERTENSIVE LIVER TRANSPLANT PATIENT. Transplantation, 1999, 68, 1211.	1.0	3
558	Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. British Journal of Pharmacology, 1998, 125, 1471-1476.	5.4	31

#	ARTICLE	IF	CITATIONS
559	Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits. <i>Atherosclerosis</i> , 1998, 137, 71-76.	0.8	26
560	Hypobetalipoproteinemia associated with apo B-48.4, a truncated protein only 14 amino acids longer than apo B-48. <i>Atherosclerosis</i> , 1998, 137, 125-131.	0.8	9
561	Dual effects of the antioxidant agents probucol and carvedilol on proliferative and fatty lesions in hypercholesterolemic rabbits. <i>Atherosclerosis</i> , 1998, 141, 45-51.	0.8	21
562	Antioxidants and coronary artery disease. <i>Current Opinion in Lipidology</i> , 1998, 9, 541-549.	2.7	21
563	Antioxidant Effect of Flavonoids. <i>Angiology</i> , 1997, 48, 39-44.	1.8	80
564	Decreased intracellular degradation and increased secretion of apo B-100 in Hep G2 cells after inhibition of cholesteryl ester synthesis. <i>Atherosclerosis</i> , 1997, 130, 143-152.	0.8	17
565	Simvastatin Modulates the Heat Shock Response and Cytotoxicity Mediated by Oxidized LDL in Cultured Human Endothelial Smooth Muscle Cells. <i>Biochemical and Biophysical Research Communications</i> , 1997, 231, 437-441.	2.1	30
566	A new fluorometric method for measuring the action of C apolipoproteins on milk lipoprotein lipase. <i>Clinica Chimica Acta</i> , 1997, 264, 75-90.	1.1	3
567	Stress proteins and atherosclerosis. <i>Atherosclerosis</i> , 1996, 127, 147-154.	0.8	37
568	Effect of the apolipoprotein C-II-C-III ratio on the capacity of purified milk lipoprotein lipase to hydrolyse triglycerides in monolayer vesicles. <i>Atherosclerosis</i> , 1996, 127, 205-212.	0.8	18
569	Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits. <i>British Journal of Pharmacology</i> , 1996, 118, 215-219.	5.4	22
570	Human Endothelial Cells Exposed to Oxidized LDL Express hsp70 Only When Proliferating. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 1104-1111.	2.4	29
571	Oxidized Ldl Trigger the Expression of Hsp70 in Cultured Endothelial Cells. <i>Medical Science Symposia Series</i> , 1996, , 603-612.	0.0	0
572	Oxidized LDL induce hsp70 expression in human smooth muscle cells. <i>FEBS Letters</i> , 1995, 372, 1-5.	2.8	34
573	Pharmacology of competitive inhibitors of HMg-CoA reductase. <i>Pharmacological Research</i> , 1995, 31, 9-27.	7.1	225
574	Fibrates: Modes of Action. <i>Medical Science Symposia Series</i> , 1995, , 295-306.	0.0	0
575	Oxidized-LDL Induce the Expression of Heat Shock Protein 70 in Human Endothelial Cells. <i>Biochemical and Biophysical Research Communications</i> , 1994, 200, 389-394.	2.1	59
576	A new case of apo C-II deficiency with a nonsense mutation in the apo C-II gene. <i>Clinica Chimica Acta</i> , 1994, 224, 111-118.	1.1	7

#	ARTICLE	IF	CITATIONS
577	Protection of low-density lipoprotein from oxidation by 3,4-dihydroxyphenylethanol. <i>Lancet, The</i> , 1994, 343, 1296-1297.	13.7	42
578	Unique Epitope of Apolipoprotein A-I Expressed in Pre-beta-1 High-Density Lipoprotein and Its Role in the Catalyzed Efflux of Cellular Cholesterol. <i>Biochemistry</i> , 1994, 33, 6981-6985.	2.5	85
579	Reduction of Lp(a) plasma levels by bezafibrate. <i>Atherosclerosis</i> , 1993, 100, 127-128.	0.8	21
580	Immunoreactivity of apo B towards monoclonal antibodies that inhibit the LDL-receptor interaction: effects of LDL oxidation. <i>Atherosclerosis</i> , 1993, 101, 37-41.	0.8	7
581	SIM 6080, A New Calcium Antagonist, Reduces Aortic Atherosclerosis in Cholesterol-Fed Rabbits. <i>Pharmacological Research</i> , 1993, 28, 219-228.	7.1	6
582	Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease.. <i>Journal of Clinical Investigation</i> , 1993, 91, 677-683.	8.2	80
583	Defective Catabolism of Oxidized LDL by J774 Murine Macrophages. <i>Medical Science Symposia Series</i> , 1993, , 427-439.	0.0	0
584	Causes Underlying the Reduced Response to Simvastatin Treatment in Hypercholesterolemic Patients. , 1993, , 207-229.		0
585	Ability of the LDL receptor from several animal species to recognize the human apo B binding domain: studies with LDL from familial defective apo B-100. <i>Atherosclerosis</i> , 1992, 93, 95-103.	0.8	29
586	Plasma lipoproteins and cholesterol metabolism in Yoshida rats: An animal model of spontaneous hyperlipemia. <i>Life Sciences</i> , 1992, 50, 1913-1924.	4.3	20
587	Mode of action of fibrates. <i>Pharmacological Research</i> , 1992, 26, 331-340.	7.1	23
588	Characterization of a family with moderate hypercholesterolemia and binding defective low density lipoprotein. <i>European Journal of Epidemiology</i> , 1992, 8, 26-32.	5.7	0
589	Evidence for the presence of 7-hydroperoxycholest-5-en-3 β -ol in oxidized human LDL. <i>Chemistry and Physics of Lipids</i> , 1992, 62, 209-214.	3.2	50
590	Monoclonal antibodies to human low density lipoprotein identify distinct areas on apolipoprotein B-100 relevant to the low density lipoprotein-receptor interaction.. <i>Journal of Lipid Research</i> , 1992, 33, 1111-1121.	4.2	21
591	Defective catabolism of oxidized LDL by J774 murine macrophages.. <i>Journal of Lipid Research</i> , 1992, 33, 819-829.	4.2	54
592	Poor response to simvastatin in familial defective apo-B-100. <i>Lancet, The</i> , 1991, 337, 305.	13.7	16
593	Reduction of LDL production rate in ileal bypassed rabbits treated with lovastatin. <i>Pharmacological Research</i> , 1991, 23, 129-137.	7.1	1
594	Cholesterol stimulation of HDL binding to human endothelial cells EAhy 926 and skin fibroblasts: evidence for a mechanism independent of cellular metabolism. <i>Lipids and Lipid Metabolism</i> , 1991, 1083, 94-100.	2.6	14

#	ARTICLE	IF	CITATIONS
595	Familial defective apo B-100, characterization of an Italian family. European Journal of Clinical Investigation, 1991, 21, 389-397.	3.4	22
596	Abnormalities of Apolipoprotein B Metabolism in the Lipid Clinic. , 1991, , 79-89.		0
597	Lecithin cholesterol acyl transferase deficiency: molecular analysis of a mutated allele. Human Genetics, 1990, 85, 195-9.	3.8	54
598	Effect of simvastatin in subjects with familial defective apolipoprotein B-100. Pharmacological Research, 1990, 22, 129.	7.1	0
599	Oxidized LDL increase free cholesterol and fail to stimulate cholesterol esterification in murine macrophages. Biochemical and Biophysical Research Communications, 1990, 171, 123-131.	2.1	47
600	Immunochemical characterization of six monoclonal antibodies to human apolipoprotein A-I: epitope mapping and expression.. Journal of Lipid Research, 1990, 31, 375-384.	4.2	17
601	Effects of calcium antagonists on lipids and atherosclerosis. American Journal of Cardiology, 1989, 64, 1129-1134.	1.6	45
602	BINDING-DEFECTIVE LOW-DENSITY LIPOPROTEIN IN FAMILY WITH HYPERCHOLESTEROLAEMIA. Lancet, The, 1989, 333, 623.	13.7	15
603	Effects of coffee on plasma lipids, lipoproteins and apolipoproteins. Pharmacological Research, 1989, 21, 27-38.	7.1	9
604	Effect of bezafibrate on plasma lipid in a strain of genetically hypercholesterolemic rco rats. Pharmacological Research, 1989, 21, 109-110.	7.1	2
605	Plasma lipoproteins and cholesterol metabolism in spontaneously hyperlipemic rats. Atherosclerosis, 1989, 76, 163-171.	0.8	14
606	Assimilation of LDL by experimental tumours in mice. Lipids and Lipid Metabolism, 1989, 1003, 301-306.	2.6	40
607	Monoclonal antibody 5A binds apolipoprotein B-48 and inhibits the low density lipoprotein-receptor interaction. Biochemical and Biophysical Research Communications, 1989, 162, 908-915.	2.1	4
608	The low density lipoprotein receptor: Structure, function and pharmacological modulation. , 1989, 43, 187-219.		10
609	Evaluation of apolipoproteins A-I and B as markers of angiographically assessed coronary artery disease. Research in Clinic and Laboratory, 1988, 18, 319-328.	0.3	9
610	Progesterone modulates the expression of HDL binding sites in human skin fibroblasts. Atherosclerosis, 1988, 74, 107-113.	0.8	6
611	The Antiatherosclerotic Effect of Anipamil in Cholesterol-Fed Rabbits. Annals of the New York Academy of Sciences, 1988, 522, 519-521.	3.8	24
612	A study of the structure of the gene for lecithin: Cholesterol acyltransferase in four unrelated individuals with familial lecithin: Cholesterol acyltransferase deficiency. Clinical Science, 1988, 74, 91-96.	4.3	16

#	ARTICLE	IF	CITATIONS
613	Activation of lipoprotein lipase by apolipoprotein C-II is modulated by the COOH terminal region of apolipoprotein C-III. <i>Chemistry and Physics of Lipids</i> , 1987, 45, 39-47.	3.2	12
614	Experimental hypothyroidism modulates the expression of the low density lipoprotein receptor by the liver. <i>Atherosclerosis</i> , 1986, 59, 329-333.	0.8	70
615	Cholesterol feeding to rats does not modulate the expression of binding sites for HDL on liver membranes. <i>Experientia</i> , 1986, 42, 1155-1157.	1.2	4
616	Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia.. <i>Journal of Clinical Investigation</i> , 1986, 78, 940-946.	8.2	30
617	Bile lipid composition and haemostatic variables in a case of high density lipoprotein deficiency (Tangier disease). <i>European Journal of Clinical Investigation</i> , 1984, 14, 49-54.	3.4	27
618	Effects of insulin deficiency on the catabolism of plasma lipoproteins and on the expression of hepatic lipoprotein receptors in rats. <i>Pharmacological Research Communications</i> , 1984, 16, 539-548.	0.2	7
619	In vivo assimilation of low density lipoproteins by a fibrosarcoma tumour line in mice. <i>Cancer Letters</i> , 1984, 25, 203-208.	7.2	65
620	β_2 -adrenergic receptors in brain microvessels of diabetic rats. <i>Life Sciences</i> , 1984, 34, 1095-1100.	4.3	27
621	Effects of probucol on the in vivo plasma clearance of human low density lipoproteins in rabbits and on the expression of lipoprotein receptors in vitro. <i>Atherosclerosis</i> , 1984, 52, 309-316.	0.8	8
622	Comparative in vitro study of the pro-apolipoprotein A-I to apolipoprotein A-I converting activity between normal and Tangier plasma.. <i>Journal of Clinical Investigation</i> , 1984, 74, 1098-1103.	8.2	15
623	Experimental studies on the hypolipidemic activity of chloridarol. <i>Pharmacological Research Communications</i> , 1983, 15, 201-215.	0.2	7
624	Effect of partial ileal bypass on plasma clearance and binding of lipoproteins to liver membranes in the rabbit. <i>Atherosclerosis</i> , 1983, 46, 269-273.	0.8	12
625	Plasma lipids, lipoproteins and apoproteins in a case of apo C-II deficiency. <i>Clinica Chimica Acta</i> , 1983, 130, 317-327.	1.1	38
626	A New Case of Familial LCAT Deficiency. <i>Acta Medica Scandinavica</i> , 1983, 214, 173-176.	0.0	17
627	Apolipoprotein C-II and lipoprotein lipase activity. <i>Research in Clinic and Laboratory</i> , 1982, 12, 35-40.	0.3	9
628	Formation of high density lipoprotein-like particles from chylomicrons. <i>Research in Clinic and Laboratory</i> , 1982, 12, 51-62.	0.3	0
629	Pharmacological studies on tiadenol in type IV patients Evidence for a mechanism of action different from other lipid-lowering drugs. <i>Atherosclerosis</i> , 1981, 40, 245-255.	0.8	6
630	Abnormal suppression of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by hypertriglyceridemic very low density lipoprotein subclasses. <i>Lipids</i> , 1980, 15, 456-463.	1.7	42

#	ARTICLE	IF	CITATIONS
631	The distribution of apo C-II and apo C-III in very low density lipoproteins of normal and type iv subjects. Atherosclerosis, 1980, 35, 419-424.	0.8	45
632	ACTIVATION OF LIPOPROTEIN LIPASE BY SYNTHETIC FRAGMENTS OF APOLIPOPROTEIN C-II. Annals of the New York Academy of Sciences, 1980, 348, 213-223.	3.8	53
633	Activation of Lipoprotein Lipase by Synthetic Fragments of ApoC-II. , 1980, , 397-400.		0
634	Glycosaminoglycans and lipoprotein metabolism: An overview. Pharmacological Research Communications, 1979, 11, 571-583.	0.2	7
635	Lipolysis of ApoC-II deficient very low density lipoproteins: Enhancement of lipoprotein lipase action by synthetic fragments of ApoC-II. Biochemical and Biophysical Research Communications, 1979, 89, 951-957.	2.1	71
636	Suppression of 3-hydroxy-3-methylglutaryl-CoA reductase by low density lipoproteins produced in vitro by lipoprotein lipase action on nonsuppressive very low density lipoproteins.. Journal of Biological Chemistry, 1979, 254, 1007-1009.	3.4	41
637	Metformin: An antiatherosclerotic agent modifying very low density lipoproteins in rabbits. Atherosclerosis, 1977, 26, 79-89.	0.8	37
638	Very low density lipoproteins in normal and cholesterol-fed rabbits: lipid and protein composition and metabolism. Atherosclerosis, 1976, 23, 85-96.	0.8	57
639	Knowledge-Based Governance Can Improve the Elderly Population's Equity of Access to Public Pharmaceutical Funding: The ASSET (Age/Sex Standardised Estimates of Treatment) Research Model. SSRN Electronic Journal, 0, , .	0.4	0
640	The Role of Registers in Increasing Knowledge and Improving Management of Children and Adolescents Affected by Familial Hypercholesterolemia: the LIPIGEN Pediatric Group. Frontiers in Genetics, 0, 13, .	2.3	4